LOS ANGELES, July 3, 2024
-- B. Riley Securities, Inc. ("B. Riley"), a leading middle market investment bank, is
pleased to have led a $46.9 million financing for Radiopharm Theranostics
Limited (RAD or "The Company"), an ASX listed clinical stage biotechnology
company developing targeted radiopharmaceutical therapies and diagnostics for
multiple types of cancer. The financing consisted of a $4.99 million strategic
investment and a $41.9 million institutional placement.
B. Riley acted as financial advisor to RAD and facilitated the strategic
investment and asset rights and development agreement with Lantheus (LNTH), an
ASX listed clinical stage biopharmaceutical company that develops and
commercializes products for imaging, cardiology, and endocrinology, and then
led the placement financing. For more information about the deal, click here.
Patrice McNicoll, Co-Head of Investment Banking at B. Riley Securities,
commented, "We are excited to partner with RAD, helping them continue their
important work developing the next generation of targeted radiotherapies and
diagnostics to fight cancer. We were able to leverage our expertise within
radiopharma, in addition to strategic and investor relationships to effectuate
a transformative transaction. The capital we helped RAD raise fully funds the
pipeline through multiple clinical data readouts."
B. Riley's investment banking team was led by Patrice McNicoll, Matt Feinberg, Brian Taylor, Melissa Woodson and Daniel Lewis,
and included Connor Boyle and Noah Rich.
Our capital markets team was led by Chad Ritchie and included Dawn Farrell, Kathy Innis and Sam Cook.
About B. Riley Securities
B. Riley has served as a preeminent fixture in middle market brokerage and
investment banking for over 25 years. We provide a full suite of investment
banking and capital markets services to companies, financial sponsors, and
institutional investors across all industry verticals. Investment banking
services include initial, secondary and follow-on offerings, institutional
private placements, merger and acquisition (M&A) advisory, SPACs, debt
financings, corporate restructuring and recapitalization. Widely recognized for
our thematic proprietary equity research, clients benefit from B. Riley's
extensive network, industry expertise, and proven execution capabilities of our
end-to-end financial services platform. Please see disclosures about B. Riley
Securities Research here. The firm is a subsidiary of B. Riley
Financial (Nasdaq: RILY). For more information, visit www.brileysecurities.com.